Central Nervous System

PV QA 2 - Poster Viewing Q&A 2

MO_9_2698 - Survival Effect Difference of Whole-Brain Radiation Therapy and TKIs in Patients with Brain Metastases from Non-Small Cell Lung Cancer Stratified by EGFR Mutation Status

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Survival Effect Difference of Whole-Brain Radiation Therapy and TKIs in Patients with Brain Metastases from Non-Small Cell Lung Cancer Stratified by EGFR Mutation Status
Z. Li, J. Zhang, D. Shen, J. Zhang, H. Han, D. Kong, J. Kong, and A. Zhang; The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Purpose/Objective(s): To compare overall (OS) and intracranial progression-free survival (iPFS) effects of whole-brain radiotherapy (WBRT) and tyrosine kinase inhibitors (TKIs) in NSCLC patients with brain metastases (BM) stratified by EGFR mutation status (positive+, negative-, unknown)

Materials/Methods: We performed a retrospective analysis of 595 NSCLC BM patients diagnosed in 2013-2015 and followed-up to December 1 2016. The stratified K-M curves and multivariate Cox models were used to evaluate effects of WBRT (defined as ≥30Gy, ' W ') and TKIs application (after BM, ' T ') on OS and iPFS independently and jointly. Covariates includes sex, age, KPS,CVD,NSCLC history length, resection of primary tumor, number of BM lesions, brain/brainstem/meningeal involvement status, BM resection, BM chemotherapy after screening. two-sided p>0.05 as ns.

Results: BM age mean (range) was 59 (22 - 87) and female 44%. Overall MTS of OS and iPFS were 9.3 and 8.9 months respectively. EGFR+ (114 pts, 53% of mutation tests), W+31% and T+76%. Multivariate HR(p) of W+ and T+ were OS - 0.768 (ns), 0.180 (0.00), iPFS - 1.057(ns) and 0.255 (0.00). Compared with W-T- (14 pts), multivariate HR(p) of W+T+(22 pts),W-T+(65) and W+T- (13) were OS - 0.196 (0.00), 0.114 (0.00), 0.434 (ns) and iPFS - 0.272 (0.01), 0.200 (0.00), 0.622 (ns). W+T+ vs. W-T+ had OS 1.717(ns) and iPFS 1.361 (ns). EGFR- (101 pts), W+43%. Multivariate HR(p) of W+ vs. W- were OS - 0.539 (0.11), iPFS - 0.485(0.05). EGFR unknown (380 pts), W+38%, T+17%. Compared with W-T- (202 pts), multivariate HR(p) of W+T+(30 pts),W-T+(35) and W+T- (113) were OS-0.304 (0.00), 0.370 (0.00), 0.465 (ns) and iPFS - 0.365(0.00), 0.556 (0.01), 0.562 (ns). W+T+ vs. W-T+ had OS 0.821(ns) and iPFS 0.657 (ns).

Conclusion: Compared with EGFR-, TKIs use in EGFR+ or EGFR-unknown patients reduces the survival effect of WBRT on OS and iPFS in patients with NSCLC brain metastases. Whether to delay WBRT in TKIs users for EGFR+ BM patients for better survival or QoL benefit deserves RCTs.

Author Disclosure: Z. Li: None. J. Zhang: None. D. Shen: None. H. Han: None.

Send Email for Zhensheng Li


Assets

MO_9_2698 - Survival Effect Difference of Whole-Brain Radiation Therapy and TKIs in Patients with Brain Metastases from Non-Small Cell Lung Cancer Stratified by EGFR Mutation Status



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Survival Effect Difference of Whole-Brain Radiation Therapy and TKIs in Patients with Brain Metastases from Non-Small Cell Lung Cancer Stratified by EGFR Mutation Status